OR WAIT 15 SECS
Through the agreement, Catalent will manufacture Trizell’s Phase I cell therapy for the treatment of micro- and macroangiopathies at its Belgium facility.
Catalent announced on Feb. 8, 2021 that it has entered into an agreement with Trizell, a German biotech company, to manufacture Trizell’s Phase I cell therapy for the treatment of micro- and macroangiopathies.
Under the terms of the agreement, development of the cell therapy will take place at the University Medical Center Schleswig Holstein, Department of Anesthesiology and Intensive Care Medicine, the Clinic for Applied Cellular Medicine, and the Department of Cardiovascular Surgery, while the manufacturing will take place at Catalent’s facility in Gosselies, Belgium, Catalent said in a company press release.
“This is an important milestone for Trizell and the therapy for the treatment of macro- and microangiopathies,” said Sibille Engels, PhD, CEO, Trizell, in the press release. “I am delighted to enter into this collaboration with Catalent and to benefit from its outstanding expertise in cell and gene therapy manufacturing.”
“Our relationship with Trizell will build on Catalent’s deep knowledge in immunotherapies, from the diagnosis and de-risk stage all the way through to commercial-ready processes,” added Manja Boerman, PhD, president, Catalent Cell & Gene Therapy, in the press release. “Extending into areas such as macrophages, allows us to stay on the forefront of emerging indications and cell types. The process development, manufacturing expertise, and the experienced production teams we have at Gosselies will enable a faster transition from development to manufacturing.”